Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Total Liabilities (2020 - 2025)

Cytek Biosciences' Total Liabilities history spans 6 years, with the latest figure at $119.8 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 15.46% year-over-year to $119.8 million; the TTM value through Dec 2025 reached $119.8 million, up 15.46%, while the annual FY2025 figure was $119.8 million, 15.46% up from the prior year.
  • Total Liabilities reached $119.8 million in Q4 2025 per CTKB's latest filing, up from $116.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $119.8 million in Q4 2025 to a low of -$1.1 million in Q1 2021.
  • Average Total Liabilities over 5 years is $87.9 million, with a median of $100.2 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: surged 7230.64% in 2022, then fell 6.22% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $57.9 million in 2021, then soared by 62.17% to $93.9 million in 2022, then increased by 7.95% to $101.4 million in 2023, then grew by 2.34% to $103.8 million in 2024, then rose by 15.46% to $119.8 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Total Liabilities are $119.8 million (Q4 2025), $116.3 million (Q3 2025), and $115.8 million (Q2 2025).